Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that lacks the expression of ER, PR, and Her-2 proteins, accounting for 15%-20% of all breast cancers.TNBC patients do not benefit from endocrine therapy or HER-2-targeted therapy, but are sensitive to cytotoxic drug therapy.Although the survival of TNBC patients has improved significantly compared with the past, it is still the type with the worst prognosis among all subtypes of breast cancer. Methods and drugs to further improve the therapeutic effect of TNBC patients are still being explored. Camrelizumab, a PD-1 in

Trial Details

NCT ID

NCT05475678

Phase

PHASE2

Sponsor

Zhenzhen Liu

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• （Carrelizumab + TCb） regimen
• TCb regimen

Locations (sample)

• Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

• Age: 18-70 years old
• cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically；
• Pathologically proven triple negative breast cancer:
• Triple-negative breast cancer is defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →